(Q39673107)

English

Synthesis, activity, and pharmacokinetic properties of a series of conformationally-restricted thiourea analogs as novel hepatitis C virus inhibitors

scientific article published on July 8, 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Synthesis, activity, and pharmacokinetic properties of a series of conformationally-restricted thiourea analogs as novel hepatitis C virus inhibitors (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Hepatitis C virus

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Iou-Jiun Kang

1

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Li-Wen Wang

2

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Teng-Kuang Yeh

3

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Chung-Chi Lee

4

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Yen-Chun Lee

5

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Sheng-Ju Hsu

6

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Yen-Shian Wu

7

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Jing-Chyi Wang

8

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Yu-Sheng Chao

9

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Andrew Yueh

10

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Jyh-Haur Chern

11

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

language of work or name

0 references

publication date

8 July 2010

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

full work available at URL

https://api.elsevier.com/content/article/PII:S0968089610006450?httpAccept=text/xml

1 reference

10.1016/J.BMC.2010.07.002

https://api.crossref.org/works/10.1016/J.BMC.2010.07.002

14 June 2024

https://api.elsevier.com/content/article/PII:S0968089610006450?httpAccept=text/plain

1 reference

10.1016/J.BMC.2010.07.002

https://api.crossref.org/works/10.1016/J.BMC.2010.07.002

14 June 2024

Bioorganic & Medicinal Chemistry

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

18

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

6414-6421

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

1

1 reference

10.1016/J.BMC.2010.07.002

https://api.crossref.org/works/10.1016/J.BMC.2010.07.002

14 June 2024

Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region

2

1 reference

10.1016/J.BMC.2010.07.002

https://api.crossref.org/works/10.1016/J.BMC.2010.07.002

14 June 2024

Viral heterogeneity of the hepatitis C virus

3

1 reference

10.1016/J.BMC.2010.07.002

https://api.crossref.org/works/10.1016/J.BMC.2010.07.002

14 June 2024

Genetic diversity and evolution of hepatitis C virus--15 years on

4

1 reference

10.1016/J.BMC.2010.07.002

https://api.crossref.org/works/10.1016/J.BMC.2010.07.002

14 June 2024

Epidemiology of hepatitis C: geographic differences and temporal trends

7

1 reference

10.1016/J.BMC.2010.07.002

https://api.crossref.org/works/10.1016/J.BMC.2010.07.002

14 June 2024

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

8

1 reference

10.1016/J.BMC.2010.07.002

https://api.crossref.org/works/10.1016/J.BMC.2010.07.002

14 June 2024

Epidemiology of hepatitis C virus (HCV) infection

9

1 reference

10.1016/J.BMC.2010.07.002

https://api.crossref.org/works/10.1016/J.BMC.2010.07.002

14 June 2024

The changing epidemiology of hepatitis C virus infection in Europe

10

1 reference

10.1016/J.BMC.2010.07.002

https://api.crossref.org/works/10.1016/J.BMC.2010.07.002

14 June 2024

Hepatitis C: progress and problems

11

1 reference

10.1016/J.BMC.2010.07.002

https://api.crossref.org/works/10.1016/J.BMC.2010.07.002

14 June 2024

Risk factors for the rising rates of primary liver cancer in the United States

12

1 reference

10.1016/J.BMC.2010.07.002

https://api.crossref.org/works/10.1016/J.BMC.2010.07.002

14 June 2024

Emerging therapies for hepatitis C virus infection

14

1 reference

10.1016/J.BMC.2010.07.002

https://api.crossref.org/works/10.1016/J.BMC.2010.07.002

14 June 2024

Novel approaches to the treatment of hepatitis C virus infection

15

1 reference

10.1016/J.BMC.2010.07.002

https://api.crossref.org/works/10.1016/J.BMC.2010.07.002

14 June 2024

The treatment of chronic viral hepatitis

16

1 reference

10.1016/J.BMC.2010.07.002

https://api.crossref.org/works/10.1016/J.BMC.2010.07.002

14 June 2024

Course and outcome of hepatitis C

17

1 reference

10.1016/J.BMC.2010.07.002

https://api.crossref.org/works/10.1016/J.BMC.2010.07.002

14 June 2024

The nature of interferon-alpha resistance in hepatitis C virus infection

19

1 reference

10.1016/J.BMC.2010.07.002

https://api.crossref.org/works/10.1016/J.BMC.2010.07.002

14 June 2024

Pathogenesis, diagnosis and management of hepatitis C.

20

1 reference

10.1016/J.BMC.2010.07.002

https://api.crossref.org/works/10.1016/J.BMC.2010.07.002

14 June 2024

Perspectives for a vaccine against hepatitis C virus

21

1 reference

10.1016/J.BMC.2010.07.002

https://api.crossref.org/works/10.1016/J.BMC.2010.07.002

14 June 2024

Immunoprophylaxis of hepatitis C virus infection.

22

1 reference

10.1016/J.BMC.2010.07.002

https://api.crossref.org/works/10.1016/J.BMC.2010.07.002

14 June 2024

Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV.

23

1 reference

10.1016/J.BMC.2010.07.002

https://api.crossref.org/works/10.1016/J.BMC.2010.07.002

14 June 2024

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

25

1 reference

10.1016/J.BMC.2010.07.002

https://api.crossref.org/works/10.1016/J.BMC.2010.07.002

14 June 2024

Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials

26

1 reference

10.1016/J.BMC.2010.07.002

https://api.crossref.org/works/10.1016/J.BMC.2010.07.002

14 June 2024

Peginterferon and ribavirin for chronic hepatitis C.

27

1 reference

10.1016/J.BMC.2010.07.002

https://api.crossref.org/works/10.1016/J.BMC.2010.07.002

14 June 2024

Clinical consequences of hepatitis C virus infection.

28

1 reference

10.1016/J.BMC.2010.07.002

https://api.crossref.org/works/10.1016/J.BMC.2010.07.002

14 June 2024

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

29

1 reference

10.1016/J.BMC.2010.07.002

https://api.crossref.org/works/10.1016/J.BMC.2010.07.002

14 June 2024

Control of hepatitis C: a medicinal chemistry perspective

30

1 reference

10.1016/J.BMC.2010.07.002

https://api.crossref.org/works/10.1016/J.BMC.2010.07.002

14 June 2024

Novel cell culture systems for the hepatitis C virus

32

1 reference

10.1016/J.BMC.2010.07.002

https://api.crossref.org/works/10.1016/J.BMC.2010.07.002

14 June 2024

Design, synthesis, and anti-HCV activity of thiourea compounds

33

1 reference

10.1016/J.BMC.2010.07.002

https://api.crossref.org/works/10.1016/J.BMC.2010.07.002

14 June 2024

A reporter-based assay for identifying hepatitis C virus inhibitors based on subgenomic replicon cells

34

1 reference

10.1016/J.BMC.2010.07.002

https://api.crossref.org/works/10.1016/J.BMC.2010.07.002

14 June 2024

Synergy of a Hepatitis C Virus (HCV) NS4A Antagonist in Combination with HCV Protease and Polymerase Inhibitors

35

1 reference

10.1016/J.BMC.2010.07.002

https://api.crossref.org/works/10.1016/J.BMC.2010.07.002

14 June 2024

Selection of Replicon Variants Resistant to ACH-806, a Novel Hepatitis C Virus Inhibitor with No Cross-Resistance to NS3 Protease and NS5B Polymerase Inhibitors

36

1 reference

10.1016/J.BMC.2010.07.002

https://api.crossref.org/works/10.1016/J.BMC.2010.07.002

14 June 2024

Biotransformation of 6-methoxy-3-(3',4',5'-trimethoxy-benzoyl)-1H-indole (BPR0L075), a novel antimicrotubule agent, by mouse, rat, dog, and human liver microsomes.

37

1 reference

10.1016/J.BMC.2010.07.002

https://api.crossref.org/works/10.1016/J.BMC.2010.07.002

14 June 2024

Identifiers

10.1016/J.BMC.2010.07.002

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39673107&oldid=2179134335"